Scientists at Johns Hopkins have discovered how a natural RNA molecule can block HIV from reactivating, opening doors to a ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized ...

Data supports further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma. SAN DIEGO, Calif., July 17, 2025 (GLOBE NEWSWIRE) - ...

Since starting operations in North Carolina 30 years ago, Biogen has spent approximately $10 billion to bolster its ...

4 analysts have shared their evaluations of WAVE Life Sciences WVE -3.57% + Free Alerts during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina.

DelveInsight's " Autosomal Dominant Optic Atrophy Market Insight, Epidemiology And Market Forecast - 2034 " report delivers comprehensive insights into the autosomal dominant optic atrophy treatment ...